Vaccination in Nile tilapia broodstock with whole cell vaccine and disease resistance in its fry against Aeromonas hydrophila

ABSTRACT The aim of this study was to analyze the effectivity of vaccination in Nile tilapia broodstock with whole cell vaccine and disease resistance in fry tilapia against Aeromonas hydrophila. Tilapia Nirwana strain that used for this had average body weight of 185±13.23 g and were maintained in ponds sizing of (2.5×2.5×1 m3). Vaccinations that has been done through intraperitoneal injection using dose of 0.1 mL/fish, meanwhile the fish for control was injected by phosphate buffered saline (PBS). This study used complete randomized design with two treatments and three replications. Antibody level was measured by using indirect enzyme-linked immunosorbent assay (ELISA) method in the broodstock, egg, and fry. Challenge test in fry tilapia performed at the age of 5, 10, and 15 days. The results showed that vaccination in tilapia broodstock delivered a significant antibody level in broodstock, eggs, and fry (P<0.05) compared to the control. Relative percent survival of offspring at 5, 10, and 15 days were 78.26%, 70.59%, and 65.52%, respectively. As a conclusion, vaccination in tilapia broodstock was effective to improve specific and non-specific immunity, and protect fry tilapia from A. hydrophila infection through maternal immunity. Keywords: vaccination, antibody, maternal immunity, tilapia, Aeromonas hydrophila ABSTRAK Penelitian ini bertujuan untuk menganalisis efikasi vaksinasi pada induk nila dengan vaksin sel utuh dan ketahanan benih yang dihasilkan terhadap Aeromonas hydrophila. Ikan nila stain Nirwana yang digunakan dalam penelitian memiliki bobot rata-rata 185±13,23 g dan ikan dipelihara dalam kolam (2,5×2,5×1 m3). vaksinasi dilakukan melalui penyuntikan intraperitoneal dengan dosis 0,1 mL/ikan, sementara itu ikan kontrol disuntik dengan phosphate buffered saline (PBS). Penelitian ini menggunakan rancangan acak lengkap dengan dua perlakuan dan tiga ulangan. Tingkat antibodi diukur dengan menggunakan metode indirect enzyme-linked immunosorbent assay (ELISA) pada induk, telur dan benih. Uji tantang pada benih dilakukan pada umur 5, 10, dan 15 hari. Hasil penelitian menunjukan bahwa vaksinasi pada induk nila secara signifikan dapat meningkatkan level antibodi pada induk, telur, dan benih (P<0,05) dibandingkan dengan kontrol. Kelangsungan hidup relatif pada benih berumur 5, 10, dan 15 hari masing-masing adalah 78,26%; 70,59%; dan 65,52%. Sebagai kesimpulan vaksinasi pada induk nila efektif dalam memperbaiki imunitas spesifik dan non spesifik serta melindungi benih dari infeksi A. hydrophila melalui imunitas maternal. Kata kunci: vaksinasi, antibodi, imunitas maternal, ikan nila, Aeromonas hydrophila

Download Full-text

Vaccination in Nile tilapia broodstock with whole cell vaccine and disease resistance in its fry against Aeromonas hydrophila

Jurnal Akuakultur Indonesia ◽

10.19027/jai.16.2.279-287 ◽

2017 ◽

Vol 16 (2) ◽

pp. 279

Author(s):

Sukenda Sukenda ◽

Odang Carman ◽

Rahman Rahman ◽

Dendi Hidayatullah ◽

Nurfitriani Siti Yumaidawati

Keyword(s):

Disease Resistance ◽

Immunosorbent Assay ◽

Antibody Level ◽

Aeromonas Hydrophila ◽

Nile Tilapia ◽

Cell Vaccine ◽

Enzyme Linked Immunosorbent Assay ◽

Whole Cell ◽

Whole Cell Vaccine ◽

Phosphate Buffered Saline

ABSTRACT The aim of this study was to analyze the effectivity of vaccination in Nile tilapia broodstock with whole cell vaccine and disease resistance in fry tilapia against Aeromonas hydrophila. Tilapia Nirwana strain that used for this had average body weight of 185±13.23 g and were maintained in ponds sizing of (2.5×2.5×1 m3). Vaccinations that has been done through intraperitoneal injection using dose of 0.1 mL/fish, meanwhile the fish for control was injected by phosphate buffered saline (PBS). This study used complete randomized design with two treatments and three replications. Antibody level was measured by using indirect enzyme-linked immunosorbent assay (ELISA) method in the broodstock, egg, and fry. Challenge test in fry tilapia performed at the age of 5, 10, and 15 days. The results showed that vaccination in tilapia broodstock delivered a significant antibody level in broodstock, eggs, and fry (P<0.05) compared to the control. Relative percent survival of offspring at 5, 10, and 15 days were 78.26%, 70.59%, and 65.52%, respectively. As a conclusion, vaccination in tilapia broodstock was effective to improve specific and non-specific immunity, and protect fry tilapia from A. hydrophila infection through maternal immunity. Keywords: vaccination, antibody, maternal immunity, tilapia, Aeromonas hydrophila ABSTRAK Penelitian ini bertujuan untuk menganalisis efikasi vaksinasi pada induk nila dengan vaksin sel utuh dan ketahanan benih yang dihasilkan terhadap Aeromonas hydrophila. Ikan nila stain Nirwana yang digunakan dalam penelitian memiliki bobot rata-rata 185±13,23 g dan ikan dipelihara dalam kolam (2,5×2,5×1 m3). vaksinasi dilakukan melalui penyuntikan intraperitoneal dengan dosis 0,1 mL/ikan, sementara itu ikan kontrol disuntik dengan phosphate buffered saline (PBS). Penelitian ini menggunakan rancangan acak lengkap dengan dua perlakuan dan tiga ulangan. Tingkat antibodi diukur dengan menggunakan metode indirect enzyme-linked immunosorbent assay (ELISA) pada induk, telur dan benih. Uji tantang pada benih dilakukan pada umur 5, 10, dan 15 hari. Hasil penelitian menunjukan bahwa vaksinasi pada induk nila secara signifikan dapat meningkatkan level antibodi pada induk, telur, dan benih (P<0,05) dibandingkan dengan kontrol. Kelangsungan hidup relatif pada benih berumur 5, 10, dan 15 hari masing-masing adalah 78,26%; 70,59%; dan 65,52%. Sebagai kesimpulan vaksinasi pada induk nila efektif dalam memperbaiki imunitas spesifik dan non spesifik serta melindungi benih dari infeksi A. hydrophila melalui imunitas maternal. Kata kunci: vaksinasi, antibodi, imunitas maternal, ikan nila, Aeromonas hydrophila

Download Full-text

Dose dependence specific and non-specific immune responses of Indian major carp (L. rohita Ham) to intraperitoneal injection of formalin killed Aeromonas hydrophila whole cell vaccine

Veterinary Research Communications ◽

10.1007/s11259-011-9498-2 ◽

2011 ◽

Vol 35 (8) ◽

pp. 541-552 ◽

Cited By ~ 18

Author(s):

Supriya Dash ◽

Swagat Kumar Das ◽

Juhi Samal ◽

Prasant Kumar Ojha ◽

Jayanta Kumar Patra ◽

...

Keyword(s):

Immune Responses ◽

Aeromonas Hydrophila ◽

Intraperitoneal Injection ◽

Dose Dependence ◽

Cell Vaccine ◽

Indian Major Carp ◽

Whole Cell ◽

Whole Cell Vaccine

Download Full-text

Whole Cell Vaccine

10.32388/qojyc0 ◽

2020 ◽

Author(s):

Keyword(s):

Cell Vaccine ◽

Whole Cell ◽

Whole Cell Vaccine

Download Full-text

Faculty Opinions recommendation of A Phase 1 Randomized, Placebo-controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of Inactivated Streptococcus pneumoniae Whole-cell Vaccine in Adults.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.737155235.793573973 ◽

2020 ◽

Author(s):

Charles Feldman

Keyword(s):

Streptococcus Pneumoniae ◽

Phase 1 ◽

Cell Vaccine ◽

Whole Cell ◽

Whole Cell Vaccine ◽

Blinded Trial

Download Full-text

Bordetella pertussis outer membrane vesicle vaccine confers equal efficacy in mice with milder inflammatory responses compared to a whole-cell vaccine

Scientific Reports ◽

10.1038/srep38240 ◽

2016 ◽

Vol 6 (1) ◽

Cited By ~ 23

Author(s):

René H. M. Raeven ◽

Jolanda Brummelman ◽

Jeroen L. A. Pennings ◽

Larissa van der Maas ◽

Wichard Tilstra ◽

...

Keyword(s):

Outer Membrane ◽

Bordetella Pertussis ◽

Inflammatory Responses ◽

Membrane Vesicle ◽

Cell Vaccine ◽

Outer Membrane Vesicle ◽

Whole Cell ◽

Whole Cell Vaccine ◽

Equal Efficacy

Download Full-text

Primary Immunization of Infants With an Acellular Pertussis Vaccine in a Double-Blind Randomized Clinical Trial

PEDIATRICS ◽

10.1542/peds.82.3.293 ◽

1988 ◽

Vol 82 (3) ◽

pp. 293-299

Author(s):

Margareta Blennow ◽

Marta Granström ◽

Eva Jäätmaa ◽

Patrick Olin

Keyword(s):

Clinical Trial ◽

Randomized Clinical Trial ◽

Pertussis Vaccine ◽

Acellular Pertussis Vaccine ◽

Cell Vaccine ◽

Primary Immunization ◽

Double Blind ◽

Whole Cell ◽

Whole Cell Vaccine ◽

Acellular Vaccine

The rate of adverse reactions and the immunogenicity of a two-component acellular pertussis vaccine as compared with a plain whole-cell vaccine and a placebo were evaluated for primary immunization in 319 6-month-old infants in a double-blind randomized clinical trial. The acellular vaccine produced few and mild systemic and local reactions. Fever (≥38°C) occurred in 6% to 8% of acellular vaccinees as opposed to 25% to 37% of whole-cell vaccinees. Redness (≥1 cm) appeared in 2% to 13% of the acellular vaccine and 24% to 32% of the whole-cell vaccine recipients. Antibody response to pertussis toxin measured in a neutralization test was obtained in 97% to 100% of the infants receiving either two or three doses of the acellular vaccine as compared to 59% after three doses of whole-cell vaccine.

Download Full-text

Antibody level of New Zealand children immunized with the triple vaccine DTP (diphtheria-tetanus-pertussis)

Epidemiology and Infection ◽

10.1017/s0950268800054352 ◽

1988 ◽

Vol 101 (2) ◽

pp. 405-410 ◽

Cited By ~ 2

Author(s):

R. C. H Lau

Keyword(s):

New Zealand ◽

Immunosorbent Assay ◽

Antibody Level ◽

Herd Immunity ◽

Enzyme Linked Immunosorbent Assay ◽

Igg Antibody ◽

Immunization Strategy ◽

The Mean ◽

Antibody Levels

SUMMARYEnzyme-linked immunosorbent assay (ELISA) tests were used to measure IgG antibody levels in 2638 New Zealand children who had been immunized with the triple vaccine DTP. The percentage of children immune to diphtheria decreased with age. The percentage of children immune to tetanus varied from 67.1 to 55.0%. The percentage of children with measurable antibody to pertussis increased with age. The mean percentages of children with measurable antibody or immunity to one or more DTP components were 34.2% (with 3 components), 34.4% (2 components), and 78.1% (1 component). It appears the immunization strategy for diphtheria and tetanus is satisfactory for herd immunity in New Zealand children. However, the current pertussis strategy may not be providing adequate immunity to 5-year-olds in this country.

Download Full-text

PERTUSSIS INCIDENCE AND THE EFFECT OF REVACCINATION OF PRESCHOOL AND SCHOOL CHILDREN

Russian Journal of Infection and Immunity ◽

10.15789/2220-7619-2018-3-284-294 ◽

2018 ◽

Vol 8 (3) ◽

pp. 284-294 ◽

Cited By ~ 1

Author(s):

А. M. Kostinov ◽

M. P. Kostinov

Keyword(s):

Favorable Effect ◽

Cell Vaccine ◽

School Age ◽

Pertussis Infection ◽

Whole Cell ◽

Number Of Factors ◽

Foreign Countries ◽

Incidence And Mortality ◽

Whole Cell Vaccine ◽

Cytomegalovirus Infections

The review is devoted to the analysis of pertussis incidence of children in the age group of 5–7, as well as strategies of DTP immunization with the help of the drugs in foreign countries. Mass vaccination against pertussis began in the middle of the 20th century, which contributed to a reduction in incidence and mortality rate from this infection. However, in the last decade, there has been an opposite tendency of increasing incidence of patients among children under school age, school age and adults. Atypical forms of the disease and complications due to ARVI, respiratory mycoplasmosis and cytomegalovirus infections are described in the review. Various strategies for the use of whole-cell and acellular pertussis vaccines as part of DTP drugs are described, as well as the epidemiological effect of introducing an additional booster dose of vaccine to children under school age. The expediency of revaccination of children aged 6–7 in Russia is argued, which can help to reduce the overall incidence of pertussis. The research materials related to the study of the properties of acellular anti-pertussis vaccine, such as immunogenicity and safety in comparison with whole-cell vaccine, are analyzed. The main drugs and their composition, which are used to vaccinate children against pertussis, are described in the review. It is assumed, that the increase in the incidence among children and teenagers, with the appearance of atypical forms of pertussis, is associated with a number of factors, such as the spread of new genotypes of Bordetella pertussis bacterium, emerged from mutations, as well as short duration of immunity after vaccination with acellular drugs, in comparison with whole-cell, and the use of more modern methods of detecting the pathogen. The mechanisms of the immune response due to different types of pertussis vaccines are also reviewed. It is concluded, that revaccination of children aged 6–7 with an additional fifth dose of an acellular vaccine against pertussis, as part of the DTaP instead of the Td drug, which is regulated in the National Calendar of preventive vaccinations, will have a favorable effect on the epidemic situation with pertussis infection in Russia.

Download Full-text

A Self-Assembling Whole-Cell Vaccine Antigen Presentation Platform

Journal of Bacteriology ◽

10.1128/jb.00752-17 ◽

2018 ◽

Vol 200 (15) ◽

Cited By ~ 1

Author(s):

Julie Liao ◽

Daniel R. Smith ◽

Jóhanna Brynjarsdóttir ◽

Paula I. Watnick

Keyword(s):

Vibrio Cholerae ◽

Bacterial Biofilm ◽

Cell Vaccine ◽

Secreted Protein ◽

Proof Of Concept ◽

Whole Cell ◽

Content Type ◽

Self Assembling ◽

Whole Cell Vaccine ◽

Common Infection

ABSTRACTDiarrhea is the most common infection in children under the age of 5 years worldwide. In spite of this, only a few vaccines to treat infectious diarrhea exist, and many of the available vaccines are sparingly and sporadically administered. Major obstacles to the development and widespread implementation of vaccination include the ease and cost of production, distribution, and delivery. Here we present a novel, customizable, and self-assembling vaccine platform that exploits theVibrio choleraebacterial biofilm matrix for antigen presentation. We use this technology to create a proof-of-concept, live-attenuated whole-cell vaccine that is boosted by spontaneous association of a secreted protein antigen with the cell surface. Sublingual administration of this live-attenuated vaccine to mice confers protection againstV. choleraechallenge and elicits the production of antigen-specific IgA in stool. The platform presented here enables the development of antigen-boosted vaccines that are simple to produce and deliver, addressing many of the obstacles to vaccination against diarrheal diseases. This may also serve as a paradigm for the development of broadly protective biofilm-based vaccines against other mucosal infections.IMPORTANCEDiarrheal disease is the most common infection afflicting children worldwide. In resource-poor settings, these infections are correlated with cognitive delay, stunted growth, and premature death. With the development of efficacious, affordable, and easily administered vaccines, such infections could be prevented. While a major focus of research on biofilms has been their elimination, here we harness the bacterial biofilm to create a customizable platform for cost-effective, whole-cell mucosal vaccines that self-incorporate secreted protein antigens. We use this platform to develop a sublingually administered live-attenuated prototype vaccine based onVibrio cholerae. This serves not only as a proof of concept for a multivalent vaccine against common bacterial enteric pathogens but also as a paradigm for vaccines utilizing other bacterial biofilms to target mucosal infections.

Download Full-text